CClinicalTrials.gg
Sign In
CompletedNCT02922933Updated Aug 16, 2018

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

A Phase 1 interventional study of entinostat and Omeprazole in Volunteers, Healthy Volunteers and Human Volunteers, sponsored by Syndax Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-16.

Sponsored by Syndax Pharmaceuticals · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is therefore to evaluate the effect of concomitant drugs through an increase of intra-gastric pH levels on the bioavailability of entinostat.

The primary objectives of this study are to evaluate the effect of multiple doses of omeprazole, famotidine, and the effect of an acidic beverage in combination with omeprazole on the single-dose PK profile of entinostat.

The secondary objectives are to evaluate the safety and tolerability of a single dose of entinostat when administered with multiple doses of omeprazole, famotidine, and when administered with an acidic beverage in combination with omeprazole.

Read the detailed description

This is a 3-part study. A total of 204 subjects will be dosed in this study if Parts 2 and 3 are conducted.

In Part 1, in Period 1, a single dose of entinostat will be administered. In Period 2, multiple doses of omeprazole will be administered for 5 days with a single dose of entinostat co-administered. If preliminary results in Period 2 of Part 1 indicate that omeprazole exhibits clinically significant drug-drug interaction (DDI) with entinostat, then Parts 2 and 3 will be conducted. If no DDI interaction is concluded between entinostat and omeprazole in Part 1, then neither Part 2 nor 3 will be conducted.

Part 2 will investigate the effect of multiple doses of famotidine administration on entinostat PK. In Period 1, a single dose of entinostat will be administered. In Period 2, oral doses of famotidine with a single dose of entinostat co-administered.

Part 3 will evaluate the effect of an acidic beverage co-administered with entinostat in subjects with increased gastric pH due to omeprazole treatment. In Period 1, multiple oral doses of omeprazole will be administered with a single dose of entinostat co-administered with water. In Period 2, multiple doses of omeprazole will be administered with a single dose of entinostat co-administered with an acidic beverage.

In all parts, PK samples will be taken.

02

Conditions studied

  • Volunteers
  • Healthy Volunteers
  • Human Volunteers
  • Normal Volunteers

Keywords

  • entinostat
  • Histone Deacetylase Inhibitor
  • HDAC
03

In context

Lead sponsor

Syndax Pharmaceuticals is the lead sponsor of 29 studies on the registry; 3 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adults 19-55 years of age at screening.
  • Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to first dose and throughout the study.
  • Body mass index of ≥ 18.5 at screening.
  • Medically healthy with no significant medical history, physical examination, laboratory values, vital signs, or ECGs. Liver function tests and serum bilirubin must be ≤ the upper limit of normal. Platelets, hemoglobin, and hematocrit must be > the lower limit of normal at screening.
  • Females of non-childbearing potential must have undergone sterilization procedures as noted in the protocol at least 6 months prior to first dose.
  • Non-vasectomized male subjects must agree to use a condom with spermicide or abstain from sexual intercourse during the study and until 90 days beyond dose of study drug.
  • Male subjects must agree not to donate sperm from the first dose and until 90 days beyond dose of study drug.
  • For Part 3 only, must be able to consume approximately 240 mL of a non-diet cola beverage within approximately 3 minutes.
  • Understands the study procedures in the informed consent form and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally incapacitated or has significant emotional problems at screening or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study in the opinion of the PI or designee.
  • History of presence of alcoholism or drug abuse within the past 2 years prior to dose.
  • History or presence of hypersensitivity or idiosyncratic reaction to entinostat, omeprazole, famotidine, or Coca-Cola(r) Classic.
  • History or presence of clinically significant cancer, cardiovascular disorders, acute or chronic gastrointestinal conditions in the opinion of the PI.
  • Females of childbearing potential.
  • Females with a positive pregnancy test or lactating.
  • Positive H. pylori breath test at screening for Parts 1 and .
  • Positive urine drug or alcohol results are screening or each check-in.
  • Positive urine cotinine at screening.
  • Positive results are screening for HIV, hepatitis B surface antigen, or hepatitis C virus
  • Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  • Seated heart rate lower than 40 bpm or higher than 99 bpm at screening.
  • QTcB interval (correction value of the interval between the Q and T waves on the ECG tracing using the Bazett Correction Formula) > 460 msec for males or > 480 msec for females or has ECG findings deemed abnormal by the PI or designee.
  • Estimated creatinine clearance \< 90 mL/min at screening.
  • Unable to refrain from or anticipates the use of any prescription or non-prescription medications and any drugs known to be significant inhibitors or CYP (Cytochromes 450) enzymes and/or P-gp.
  • Has been on a diet incompatible with the on-study diet within 28 days prior to dose and throughout the study in the opinion of the PI or designee.
  • Donation of blood or significant blood loss within 56 days prior to dose.
  • Plasma donation within 7 days prior to dose.
  • Participation in another clinical study 28 days prior to dose.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Omeprazole

    Treatment A: 5mg entinostat on Day 1 Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1

    Drug: entinostat · Dietary Supplement: Omeprazole

  • Active comparator
    Famotidine

    Treatment C: 5mg entinostat on Day 1 Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1

    Drug: entinostat · Dietary Supplement: Famotidine

  • Active comparator
    Acidic Beverage

    Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage

    Drug: entinostat · Dietary Supplement: Omeprazole

Interventions

  • Drugentinostat

    HDAC (histone deacetylase inhibitor)

    Also known as: SNDX-275, MS-275

  • Dietary supplementOmeprazole

    Proton pump inhibitor

    Also known as: Prilosec, Zegerid

  • Dietary supplementFamotidine

    Histamine-2 blocker

    Also known as: Pepcid

06

What researchers measure

Primary outcomes

  1. AUC0-t (area under the concentration-time curve) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage

    Time frame: Pre-dose through Day 22

  2. AUC0-inf (area under the concentration-time curve, from time 0 extrapolated to infinity for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

  3. Cmax (maximum observed concentration) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

Secondary outcomes

  1. AUC%extrap (percent of AUC0-inf extrapolated) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

  2. Tmax (time to reach maximum observed concentration) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

  3. Kel (apparent terminal elimination rate constant) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

Other outcomes

  1. T1/2 (apparent terminal elimination half-life) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

  2. CL/F (apparent total plasma clearance after oral (extravascular) administration)for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)

    Time frame: Pre-dose through Day 22

  3. Vz/F (apparent volume of distribution during the terminal elimination phase) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage

    Time frame: Pre-dose through Day 22

  4. Changes from baseline in physical exam

    Time frame: Baseline through Day 1

  5. Changes from baseline in vital signs

    Time frame: Baseline through Day 22

  6. Changes from baseline in ECG results

    Time frame: Baseline through follow Day 22

  7. Changes from baseline in clinical laboratory tests

    Time frame: Baseline through Day 1

07

Study locations

2 sites
  • Celerion
    Tempe, Arizona 85283, United States
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No — Data will be reviewed throughout the study by the sponsor, clinical research organization assisting with serious adverse event management, and routine monitoring to safeguard the interests of the trial subjects and to assess the safety of the interventions administered during the trial.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02922933
Lead sponsor
Syndax Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Oct 25, 2016
Primary completion
Apr 19, 2017
Completion
May 8, 2017
Last update
Aug 16, 2018

Study contacts

Laura Sterling, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Syndax Pharmaceuticals

Start the discussion